The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer

Masuda, Takeshi; Hirano, Chihiro; Horimasu, Yasushi; Nakashima, Toshikatsu; Miyamoto, Shintarou; Iwamoto, Hiroshi; Ohshimo, Shinichiro; Fujitaka, Kazunori; Hamada, Hironobu; Hattori, Noboru

doi:10.1007/s00280-017-3476-5

Cited by 13 publications

(15 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies determined that the presence of GGAs, not including brotic area, was a risk for conventional chemotherapy and immunotherapy-related ILD (15,16,22). We also found that the presence of non-brotic ILAs was an independent risk factor for early-onset ICI-ILD.…”

Section: Discussionsupporting

confidence: 67%

See 1 more Smart Citation

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

BackgroundInterstitial lung abnormalities (ILAs) are known to be a risk of drug-induced pneumonitis. However, there are few reports on the relationship between ILAs and immune checkpoint inhibitor-related interstitial lung disease (ICI-ILD). We retrospectively investigated the clinical signi cance of ILAs in patients with nonsmall cell lung cancer (NSCLC) receiving ICI. MethodsWe de ned ILAs as nondependent abnormalities affecting more than 5% of any lung zone, including ground-glass or diffuse centrilobular nodularities, traction bronchiectasis, honeycombing, and nonemphysematous cysts. Early-onset ICI-ILD was de ned as developing within 3 months after the initiation of ICI administration. ResultsOf 264 patients with advanced NSCLC, 57 patients (21.6%) had ILAs (43 brotic and 14 non brotic ILAs).The difference between the incidence of ICI-ILD in patients with or without ILAs was not signi cant. Of 193 patients treated by ICI monotherapy, 18 (9.3%) developed early-onset ICI-ILD. Among patients receiving ICI monotherapy, the incidence of early-onset ICI-ILD was signi cantly higher in patients with than in patients without non brotic ILAs. ConclusionThe presence of non brotic ILAs is a signi cant risk for early-onset ICI-ILD in patients with NSCLC undergoing ICI monotherapy. Clinicians should be aware of ILAs, especially non brotic ILAs, before administering ICIs to lung cancer patients.warranted to validate the present ndings. In conclusion, the presence of non brotic ILAs was a signi cant risk factor for early-onset ICI-ILD in patients about to undergo ICI monotherapy. The presence of ILAs is more likely to be associated with lung cancer then the absence of ILAs, and early-onset ICI-ILD can interfere with the treatment of lung cancer and can be life-threatening. Clinicians should bear in mind the possible presence of ILAs, especially non brotic ILAs, in patients with lung cancer, before they decide to administer ICIs.

show abstract

Section: Discussionsupporting

confidence: 67%

“…We also found that the presence of non-brotic ILAs was an independent risk factor for early-onset ICI-ILD. GGA re ects in ammation by lymphocytes in the interstitium, and ICIs exert antitumor effects via activation of lymphocytes (15,16,22). These results may explain why GGAs were involved with ICI-ILD (15,16,22).…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In fact, the % FVC of all patients enrolled in the present study was over 80%, and the % FVC was not a risk factor associated with AE-ILD. Recent reports have shown that the size of the pre-ILD area on pretreatment CT was a risk factor for chemotherapy-related lung injury in patients with both NSCLC and pre-ILD (5,17). However, the extent of pre-ILD in all cases in the present study was mild, and whether or not it was risk factor for AE-ILD could not be determined.…”

Section: Discussioncontrasting

confidence: 66%

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

et al. 2020

View full text Add to dashboard Cite

Objective Pembrolizumab has beneﬁted patients with advanced non-small-cell lung cancer (NSCLC) with a programmed death-ligand (PD-L)1 high expression, but little information is available regarding its safety for patients with interstitial lung disease (ILD). The aim of this study was to assess the efficacy and tolerability of pembrolizumab for patients with advanced NSCLC and preexisting ILD. Methods We retrospectively reviewed the medical records of five patients with advanced NSCLC and preexisting ILD who received pembrolizumab monotherapy in a first-line setting. Patients All patients had mild ILD and pulmonary emphysema with a forced vital capacity within the normal range. Pembrolizumab was administered at a dose of 200 mg/body on day 1 every 3 weeks. Results The overall response rate was 60%. Four patients developed pembrolizumab-induced lung injury, which was improved in all cases by corticosteroid therapy. One patient received pembrolizumab for two years, did not experience lung injury and achieved a complete response. Conclusion Pembrolizumab has a high risk of inducing lung injury in patients with preexisting ILD, although it may be very effective in NSCLC patients with a high PD-L1 expression, even concurrent with preexisting ILD. Further large-scale studies are needed to determine risk factors of pembrolizumab-induced lung injury in such patients.

show abstract

“…In China, studies of KL-6 have mainly focused on significant increases in the serum levels of this antigen in the context of different types of ILDs, including IPF, CVD-IP, and HP, and the results have suggested the potential diagnostic use of this parameter. In other countries, researchers have reported distinctly elevated serum KL-6 levels in patients diagnosed with IIP, radiation pneumonitis, pulmonary alveolar proteinosis, CTD-related interstitial pneumonia, non-small cell lung cancer, bronchopulmonary dysplasia in preterm infants, and neonatal high-permeability pulmonary oedema (14)(15)(16)(17). Our observation of significantly higher serum KL-6 levels in patients with IIP relative to those in patients with other lung diseases agreed with the findings of Kohno and Vij (11,18).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of KL-6 in idiopathic interstitial pneumonia

et al. 2018

View full text Add to dashboard Cite

show abstract

The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer

Abstract: The GGA area on HRCT is a risk factor for chemotherapy-related AE-ILD. Therefore, this parameter can be used to predict the risk of AE-ILD before administering chemotherapy.

Cited by 13 publications

References 35 publications

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

Diagnostic value of KL-6 in idiopathic interstitial pneumonia

Contact Info

Product

Resources

About